Li Wang1, Zhixuan Ren2, Bentong Yu3, Jian Tang4. 1. Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China. 2. Department of Oncology, TCM-Integrated Hospital of Southern Medical University, Southern Medical University, Guangzhou, 510000, China. 3. Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330000, China. 4. Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, 330000, China. rometangjian@hotmail.com.
Abstract
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC). Currently, the predictive biomarker of ICIs mainly including the expression of PD-L1, TMB, TIICs, MMR and MSI-H. However, there are no official biomarkers to guide the treatment of ICIs and to determine the prognosis. Therefore, it is essential to explore a systematic nomogram to predict the prognosis of ICIs treatment in NSCLC METHODS: In this work, we obtained gene expression and clinical data of NSCLC patients from the TCGA database. Immune-related genes (IRGs) were downloaded from the ImmPort database. The detailed clinical annotation and response data of 240 advanced NSCLC patients who received ICIs treatment were obtained from the cBioPortal for Cancer Genomics. Kaplan-Meier survival analysis was used to perform survival analyses, and selected clinical variables to develop a novel nomogram. The prognostic significance of FGFR4 was validated by another cohort in cBioPortal for Cancer Genomics. RESULTS: 3% of the NSCLC patients harbored FGFR4 mutations. The mutation of FGFR4 were confirmed to be associated with PD-L1, and TMB. Patients harbored FGFR4 mutations were found to have a better prolonged progression-free survival (PFS) to ICIs treatment (FGFR4: P = 0.0209). Here, we built and verified a novel nomogram to predict the prognosis of ICIs treatment for NSCLC patients. CONCLUSION: Our results showed that FGFR4 could serve as novel biomarkers to predict the prognosis of ICIs treatment of advanced NSCLC. Our systematic prognostic nomogram showed a great potential to predict the prognosis of ICIs for advanced NSCLC patients.
INTRODUCTION: Immune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC). Currently, the predictive biomarker of ICIs mainly including the expression of PD-L1, TMB, TIICs, MMR and MSI-H. However, there are no official biomarkers to guide the treatment of ICIs and to determine the prognosis. Therefore, it is essential to explore a systematic nomogram to predict the prognosis of ICIs treatment in NSCLC METHODS: In this work, we obtained gene expression and clinical data of NSCLCpatients from the TCGA database. Immune-related genes (IRGs) were downloaded from the ImmPort database. The detailed clinical annotation and response data of 240 advanced NSCLCpatients who received ICIs treatment were obtained from the cBioPortal for Cancer Genomics. Kaplan-Meier survival analysis was used to perform survival analyses, and selected clinical variables to develop a novel nomogram. The prognostic significance of FGFR4 was validated by another cohort in cBioPortal for Cancer Genomics. RESULTS: 3% of the NSCLCpatients harbored FGFR4 mutations. The mutation of FGFR4 were confirmed to be associated with PD-L1, and TMB. Patients harbored FGFR4 mutations were found to have a better prolonged progression-free survival (PFS) to ICIs treatment (FGFR4: P = 0.0209). Here, we built and verified a novel nomogram to predict the prognosis of ICIs treatment for NSCLCpatients. CONCLUSION: Our results showed that FGFR4 could serve as novel biomarkers to predict the prognosis of ICIs treatment of advanced NSCLC. Our systematic prognostic nomogram showed a great potential to predict the prognosis of ICIs for advanced NSCLCpatients.
Authors: Sanchita Bhattacharya; Sandra Andorf; Linda Gomes; Patrick Dunn; Henry Schaefer; Joan Pontius; Patty Berger; Vince Desborough; Tom Smith; John Campbell; Elizabeth Thomson; Ruth Monteiro; Patricia Guimaraes; Bryan Walters; Jeff Wiser; Atul J Butte Journal: Immunol Res Date: 2014-05 Impact factor: 2.829
Authors: Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes Journal: Lancet Date: 2019-04-04 Impact factor: 79.321
Authors: Neal Ready; Matthew D Hellmann; Mark M Awad; Gregory A Otterson; Martin Gutierrez; Justin F Gainor; Hossein Borghaei; Jacques Jolivet; Leora Horn; Mihaela Mates; Julie Brahmer; Ian Rabinowitz; Pavan S Reddy; Jason Chesney; James Orcutt; David R Spigel; Martin Reck; Kenneth John O'Byrne; Luis Paz-Ares; Wenhua Hu; Kim Zerba; Xuemei Li; Brian Lestini; William J Geese; Joseph D Szustakowski; George Green; Han Chang; Suresh S Ramalingam Journal: J Clin Oncol Date: 2019-02-20 Impact factor: 44.544
Authors: Dukagjin M Blakaj; Marcelo Bonomi; Majd Issa; Brett G Klamer; Nikol Mladkova; Georgios I Laliotis; Vidhya Karivedu; Priyanka Bhateja; Chase Byington; Khaled Dibs; Xueliang Pan; Arnab Chakravarti; John Grecula; Sachin R Jhawar; Darrion Mitchell; Sujith Baliga; Matthew Old; Ricardo L Carrau; James W Rocco Journal: BMC Cancer Date: 2022-07-14 Impact factor: 4.638